Kun Qian

Dr. Kun Qian


Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 August 2018 in Thoracic Cancer
Verified
Journal Article
Open access
PDF file
KQKun Qian
Kun Qian
YWYan Wang
Yan Wang
LHLin Hua
Lin Hua
ACAnyu Chen
Anyu Chen
YZYi Zhang
Yi Zhang
Surface‐enhanced Raman spectroscopy (SERS) is a surface‐sensitive technique that enhances Raman scattering by molecules adsorbed on nanostructures. The advantages of using SERS include high detection sensibility and fast analysis, thus it is a potentially promising tool for sensing metabolic cancer molecules in trace amounts. To explore this new method of lung cancer detection, we analyzed saliva samples from 61 lung cancer patients and 66 healthy controls. An SERS system and a nano‐modified chip were used in this study. Statistics were analyzed using support vector machine (SVM) and random forest algorithms. The leave‐one‐out algorithm was used based on SVM results to analyze differences in saliva between lung cancer patients and controls. There was a significant difference between the saliva of patients with lung cancer and healthy controls using the Raman spectrum; the intensity of the spectral line in lung cancer patients was weaker than in controls and 12 characteristic peaks were detected. Saliva SERS peaks have been characterized to refer to tissues, body fluids, and biological standard Raman peaks, but it is difficult to identify molecules with current information. The sensitivity and specificity of Raman spectroscopy data and SVM classification results of lung cancer patients and normal saliva samples were both 100%. Using the leave‐one‐out algorithm, the sensitivity was 95.08% and the specificity was 100%. The sensitivity of the random forest method was 96.72% and specificity was 100%. Our results show that SERS has the potential to detect lung cancer.

11 September 2023 in Asian Journal of Surgery
Verified
Journal Article
Open access
FHFan He
Fan He
FYFuyu Yang
Fuyu Yang
DCDefei Chen
Defei Chen
CTChenglin Tang
Chenglin Tang
SWSaed Woraikat
Saed Woraikat
KQKun Qian
Kun Qian
Radical resection of rectal cancer is a safe and effective treatment, but there remain several complications related to anastomosis. We aimed to assess the risk factors and incidence of rectal anastomotic stenosis (AS) after rectal cancer resection. We conducted a systematic review and meta-analysis after searching PubMed, Embase, Web of Science, and Medline databases from inception until May 2023. Data are reported as the combined odds ratio (OR) for categorical variables and the weighted mean difference (WMD) for continuous variables. Six hundred and fifty-nine studies were retrieved, nine (3031 patients) of which were included in the meta-analysis. Young age (WMD = -3.09, P = 0.0002), male sex (OR = 1.53, P = 0.0002), smoking (OR = 1.54, P = 0.009), radiotherapy (OR = 2.34, P = 0.0002), protective stoma (OR = 2.88, P = 0.007), intersphincteric resection surgery (OR = 6.28, P = 0.05), anastomotic fistula (OR = 3.72, P = 0.003), and anastomotic distance (WMD = -3.11, P = 0.0006) were identified as factors that increased the risk of AS, while staple (OR = 0.39, P < 0.001) was a protective factor. The incidence of AS after rectal cancer resection was approximately 17% (95% CI: 13%-21%). We identified eight risk factors and one protective factor associated with AS after rectal cancer resection. These factors may be combined in future studies to develop a more comprehensive and accurate prediction model related to AS after rectal cancer resection.

1 August 2020 in Cancer Management and Research
Verified
Journal Article
Open access
PDF file
DPDong Peng
Dong Peng
YCYu-Xi Cheng
Yu-Xi Cheng
WTWei Tao
Wei Tao
YZYing-Ying Zou
Ying-Ying Zou
KQKun Qian
Kun Qian
WZWei Zhang
Wei Zhang
Purpose: The purpose of this study was to explore the changes in blood pressure in patients with concurrent gastric cancer and hypertension after gastrectomy, and to identify the factors that affect the changes in blood pressure. Materials and Methods: Patients with concurrent gastric cancer and hypertension who underwent gastrectomy were retrospectively analyzed from January 2013 to December 2018. The pre- and 6-month postoperative medical records were compared. Predictors for the remission of hypertension were analyzed. Results: A total of 143 patients with concurrent gastric cancer and hypertension were included in this study. The number of patients with complete remission, partial remission and no remission were 67 (46.9%), 12 (8.4%) and 64 (44.7%), respectively. The average of weight and BMI (body mass index) before gastrectomy were 63.0 ± 9.7 kg and 23.4 ± 2.9 kg/m2, respectively, which were significantly higher than those 6-month postgastrectomy: 54.8 ± 9.8 kg and 20.4 ± 3.1 kg/m2, respectively (p< 0.001). The average number of antihypertensive medications before gastrectomy was 1.5 ± 0.6, while it was 0.8 ± 0.8 6-month postgastrectomy (p< 0.001). Age (p< 0.05) and the surgical techniques used (p< 0.05) were significantly different between partial remission and no remission patients. Furthermore, age (p< 0.05) and the surgical techniques used (p< 0.05) were significantly different between complete remission and no remission patients. Age (p< 0.05, odds ratio =0.933, 95% CI=0.890– 0.978) and the surgical techniques used (p< 0.05, odds ratio =2.749, 95% CI=1.132– 6.677) are predictors for remission of hypertension. Conclusion: Total gastrectomy is an onco-metabolic surgery that can cure younger patients with concurrent gastric cancer and hypertension. Age and the surgical techniques used can predict the remission of hypertension 6 months after gastrectomy.

26 February 2024 in Thoracic Cancer
Verified
Journal Article
Open access
XTXiaoru Tian
Xiaoru Tian
XLXingsheng Liu
Xingsheng Liu
KWKai Wang
Kai Wang
RWRuotian Wang
Ruotian Wang
YLYuanbo Li
Yuanbo Li
YZYi Zhang
Yi Zhang
Background: Circulating tumor DNA (ctDNA) has emerged as a potential novel biomarker to predict molecular residual disease (MRD) in lung cancer after definitive treatment. Herein, we investigated the value of ctDNA in prognosing risk of relapse and monitoring the effect of adjuvant therapy in surgical non‐small cell lung cancer (NSCLC).Methods: We enrolled 58 NSCLC patients in a real‐world setting, and 58 tumor tissues and 325 plasma samples were analyzed. Tumor tissues and plasma samples were subjected to targeted next‐generation sequencing (NGS) of 1021 cancer‐related and ultra‐deep targeted NGS covering 338 genes, respectively.Results: ctDNA was detected in 31.0% of cases at the first postoperative time, which was associated with advanced tumor stage, T stage and KEAP1 or GRIN2A mutations in tissues. ctDNA positivity at landmark and longitudinal indicated the shorter disease‐free survival. For patients with ctDNA positivity at the first postoperative time, regardless of adjuvant therapy, all patients who were persistently ctDNA positive during postoperative surveillance had disease recurrence. Among the patients who were ctDNA negative, only two patients (15.4%, 2/13) receiving adjuvant therapy relapsed, while one patient (50.0%, 1/2) without adjuvant therapy relapsed. For the first postoperative ctDNA negative patients, the recurrence rate of patients with adjuvant therapy was and higher than without adjuvant therapy (22.6% [7/31] vs. 11.1% [1/9]). The patients who became ctDNA positive may also benefit from intervention therapy.Conclusion: Postoperative ctDNA is a prognostic marker, and ctDNA‐detection may facilitate personalized adjuvant therapy, and applying adjuvant therapy to the patients with detectable ctDNA could bring clinical benefits for them.

12 September 2024 in Frontiers in Oncology
Verified
Journal Article
Open access
PDF file
FYFuyu Yang
Fuyu Yang
YYYe Yuan
Ye Yuan
WLWenwen Liu
Wenwen Liu
CTChenglin Tang
Chenglin Tang
FHFan He
Fan He
KQKun Qian
Kun Qian
Background: To improve perioperative frailty status in patients undergoing laparoscopic colorectal cancer surgery (LCCS), we explored a new intensive prehabilitation program that combines prehabilitation exercises with standard enhanced recovery after surgery (ERAS) and explored its impact.Methods: We conducted a prospective randomized controlled trial. Between April 2021 to August 2021, patients undergoing elective LCCS were randomized into the standardized ERAS (S-ERAS) group or ERAS based on prehabilitation (group PR-ERAS). Patients in the PR-ERAS group undergoing prehabilitation exercises in the perioperative period in addition to standard enhanced recovery after surgery. We explored the effects of this prehabilitation protocol on frailty, short-term quality of recovery (QoR), psychological status, postoperative functional capacity, postoperative outcomes, and pain.Results: In total, 125 patients were evaluated, and 95 eligible patients were enrolled and randomly allocated to the S-ERAS (n = 45) and PR-ERAS (n = 50) groups. The Fried score was higher in the PR-ERAS group on postoperative day (7 (2(2,3) vs. 3(2,4), P = 0.012). The QoR-9 was higher in the PR-ERAS group than in the S-ERAS group on the 1st, 2nd, 3rd, and 7th postoperative days. The PR-ERAS group had an earlier time to first ambulation (P < 0.050) and time to first flatus (P < 0.050).Conclusion: Prehabilitation exercises can improve postoperative frailty and accelerate recovery in patients undergoing LCCS but may not improve surgical safety. Therefore, better and more targeted prehabilitation recovery protocols should be explored.Clinical trial registration: www.clinicaltrials.org, identifier NCT04964856.

15 November 2018 in Frontiers in Neurology
Verified
Journal Article
Open access
PDF file
DZDao Pei Zhang
Dao Pei Zhang
HLHao Ran Li
Hao Ran Li
KQKun Qian
Kun Qian
SYSuo Yin
Suo Yin
YPYan Fang Peng
Yan Fang Peng
SZShu Ling Zhang
Shu Ling Zhang
Background and Purpose: The aim of this study was to determine the prevalence and associated factors of stroke and hypoperfusion among patients with isolated vertigo and vascular risk factors. Methods: We studied 157 patients with isolated vertigo who had undergone multimodal magnetic resonance imaging. Magnetic resonance angiography (MRA) was used to measure the diameters of vertebrobasilar arteries and to evaluate morphologic changes to vessels. Measurements obtained included length of the basilar artery and curvature index for the vertebral artery (VA). Perfusion-weighted imaging (PWI) was performed to determine relative cerebral blood flow, relative cerebral blood volume (rCBV), time to peak (TTP), and mean transit time for two mirror regions of interest (ROIs) in each map. Regional hypoperfusion of the cerebellum was considered significant when TTP and mean transit time (MTT) were present in ≥2 adjacent slices. Results: The prevalence of stroke in patients with isolated vertigo and vascular risk factors was 24.8% (n = 39). Visual assessment revealed cerebellar hypoperfusion in 57.6% (68/118) of non-stroke patients. Multivariate logistic regression indicated that diabetes mellitus (P = 0.049, OR = 2.758), VA stenosis or hypoplasia (P = 0.023, OR = 3.486), and relative TTP of cerebellum (P = 0.002, OR = 3.197) were independent risk factors for stroke and LVA curvature index (P = 0.026, OR = 2.049), VA stenosis and hypoplasia (P = 0.009, OR = 2.977) were independent risk factors for hypoperfusion. Conclusions: The prevalence of stroke and hypoperfusion is higher in patients with isolated vertigo and vascular risk factors, compared with matched controls. Potential risk factors include diabetes mellitus, VA stenosis or hypoplasia, and enlarged VA curvature index.